Actavis may have lost its court bid to "hard switch" original Namenda users to Namenda XR, but that's all the more reason to continue its aggressive marketing of the newer one-a-day Alzheimer's pill.
Spring has sprung, and so has allergy advertising. Drugmakers blast the airwaves annually as the pollen starts to fly, with the latest sniff and cough relief remedies. But this year there's a new big spender in the achoo wars--emphasis on "big." GlaxoSmithKline spent an estimated $71 million in TV advertising alone for its newly OTC nasal spray Flonase. Read more >>
Only about 30% of teens receive a second meningitis shot at age 16 as recommended by the CDC, and for vaccine maker Sanofi Pasteur, that's a problem. But the French drugmaker is hoping it can change that, and to do so, it's teaming up with a teen idol. Read more >>
Payers have promised a fight over the price of PCSK9 drugs, a new class of cholesterol fighters. Drugmakers in the field--including frontrunners Amgen and Sanofi--prepared for that fight. And now, analysts think they've defined the battle lines.
When you're targeting an under-the-radar malady that hasn't traditionally been treated with prescription drugs, it's up to marketers to get the word out and deliver on sales. And that's why AstraZeneca and Daiichi Sankyo, whose Movantik launched earlier this year, are bringing a 6-time Olympic medalist on board to talk about opioid-induced constipation (OIC).
Television ads have shown them lounging on a beach, gazing at the view from a mountaintop and watching the view from above a scenic lake. All sans clothing and facing away from the camera. We're talking about Eli Lilly's Cialis bathtub couples, of course. Yet the bathtub couples were not universally well-received at launch, and they've been oft-spoofed since.
The crowded next-gen psoriasis landscape may lose a contender, now that Amgen has bailed out of its brodalumab pact with AstraZeneca. And if the British pharma decides to go it alone, it'll face plenty of contenders--not to mention reports of side effects--that could make building market share an uphill battle.
Pharma companies that make payments to doctors--and the doctors who receive them--repeatedly insist there's no link between those payments and prescribing habits. But data on Medicare's top script writers show the highest prescribers of particular meds collect big payments from the makers of those very drugs.
While the list of the top spending DTC ad spenders changes every year, there are always a few certainties and a few surprises.